Clinical Holds Lifted On Gene Therapy Trial For MS
The FDA has recently lifted the clinical holds placed on the phase ½ clinical trial of Solid Biosciences’s gene therapy treatment for Duchenne muscular dystrophy; a clearance was secured to resume dosing in the trial after making manufacturing changes to the number of viral particles that are given to patients. The adeno-associated viral vector-mediated gene …